Senhwa Biosciences, Inc.

6492 · TWO · Healthcare / Biotechnology

29.70TWD-0.15 (-0.50%)

Price History

Full chart

Market Stats

Previous Close29.85

Open29.75

Day Range29.35 – 30.10

52-Week Range33.15 – 66.50

Volume120.62K

Market Cap3.93B

P/E (TTM)0.00

Forward P/E0.00

EPS-3.22

Dividend Yield0.00%

Beta0.75

50-Day Avg35.94

200-Day Avg45.31

About

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical advice and consulting services. Senhwa Biosciences, Inc. is based in New Taipei City, Taiwan.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Jason Huang M.D.
Employees0
HeadquartersNo. 225, Peihsin Road, New Taipei City, Taiwan, 23143, Taiwan
Websitehttps://www.senhwabio.com

Leadership

Ms. Sarah Chang CPAExecutive VP, CFO & Accounting Supervisor
Mr. Jason Huang M.D.Acting CEO & Chief Medical Officer
Ms. Joanne Lo Ph.D.Acting Chief Operating Officer & Business Development Director

Financials

Income Statement

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	550.00K	1.00M	1.00M	1.00M	1.07M
Growth (%)	-	+81.82%	0.00%	0.00%	+7.00%
Cost of Revenue	227.00K	495.00K	448.00K	523.00K	550.00K
Gross Profit	323.00K	505.00K	552.00K	477.00K	520.00K
Gross Margin	58.73%	50.50%	55.20%	47.70%	48.60%
Operating Expense	346.64M	356.62M	311.66M	306.67M	278.78M
Operating Income	-346.32M	-356.12M	-311.11M	-306.19M	-278.26M
Operating Margin	-62966.55%	-35611.50%	-31111.10%	-30619.10%	-26005.51%
EBITDA	-	-340.60M	-283.79M	-279.71M	-250.57M
EBITDA Margin	-	-34060.40%	-28378.50%	-27970.60%	-23418.22%
Net Income	-329.26M	-349.63M	-296.31M	-293.75M	-264.77M
Net Income Margin	-59864.91%	-34963.20%	-29630.60%	-29374.50%	-24744.77%
R&D	275.47M	312.85M	256.87M	243.74M	217.75M
R&D as % of Total Revenue	50084.73%	31284.80%	25687.10%	24373.60%	20350.19%
Interest Expense	526.00K	544.00K	535.00K	663.00K	753.00K
Interest Expense % of Total Revenue	95.64%	54.40%	53.50%	66.30%	70.37%

Balance Sheet

Currency: TWD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	2.06B	1.65B	1.36B	1.07B	819.26M
Total Liabilities	92.44M	40.93M	46.17M	38.92M	58.30M
Total Equity	1.97B	1.61B	1.32B	1.03B	760.96M
Cash	2.03B	1.62B	1.32B	1.03B	771.78M

Cash Flow

Currency: TWD	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-	-300.05M	-399.97M	-294.40M	-294.22M	-248.46M
Capital Expenditure	0	401.00K	369.00K	4.77M	1.95M	280.00K
Free Cash Flow	-	-300.45M	-400.34M	-299.17M	-296.17M	-248.74M
FCF to OCF	-	100.13%	100.09%	101.62%	100.66%	100.11%

Earnings

Report Date	May 11, 2018	Aug 14, 2018	Nov 14, 2018	Mar 28, 2019	May 13, 2019	Aug 11, 2019	Nov 7, 2019	Mar 24, 2020	May 13, 2020	Aug 14, 2020	Nov 12, 2020	Mar 25, 2021	May 11, 2021	Aug 10, 2021	Nov 12, 2021	Mar 11, 2022	May 12, 2022	Aug 11, 2022	Nov 10, 2022	Mar 30, 2023
EPS Estimate	-1.14	-1.11	-	-1.45	-1.16	-1.67	-1.62	-1.92	-1.54	-1.16	-1.03	-1.03	-1.03	-0.86	-1.00	-0.98	7.60	-0.95	-	-
EPS Actual	-0.83	-1.75	-1.14	-1.27	-1.83	-1.28	-1.09	-1.03	-1.13	-0.97	-1.52	-0.86	-1.02	-0.76	-0.97	-0.92	-0.87	-1.09	-0.93	-1.03
Surprise	27.19%	-57.66%	-	12.41%	-57.76%	23.35%	32.72%	46.35%	26.62%	16.38%	-47.57%	16.50%	0.97%	11.63%	3.00%	6.12%	-111.45%	-14.74%	-	-
Timing	Pre-market	After-hours	After-hours	After-hours	Pre-market	After-hours	Pre-market	After-hours	Pre-market	Pre-market	After-hours	Pre-market	After-hours	After-hours	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap3.93B

Enterprise Value3.32B

Trailing P/E0.00

Forward P/E0.00

Price / Sales3747.49

Price / Book6.38

EPS-3.22

Book Value6.90

Revenue (TTM)1.05M

Gross Profit (TTM)443.00K

EBITDA-304.34M

Profit Margin0.00%

Operating Margin-35327.50%

Return on Equity-39.03%

Return on Assets-23.57%

Shares Outstanding114.39M

Shares Float67.41M

Beta0.75

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Mar 16, 2020477.33:1000